Target intelligence / Profile preview

Brucella abortus

Molecular classification
Other (bacterial pathogen, gram-negative coccobacillus)
01

Overview

Brucella abortus is a small, gram-negative, non-motile, facultative intracellular coccobacillus that primarily infects cattle, causing late-term abortion, retained placenta, and infertility, while also serving as a major zoonotic pathogen in humans leading to brucellosis with symptoms like undulant fever, joint pain, and organ involvement. It survives and replicates within host macrophages by deploying a type IV secretion system (T4SS) to manipulate host vesicular trafficking, inhibit phagosome-lysosome fusion, and modulate ER stress responses via effectors like TcpB and Bsp proteins, thereby evading innate and adaptive immunity. Virulence factors include acid-fast cell walls, exopolysaccharide transporters like ExsA for intracellular persistence, and stress-response enzymes such as catalases for resisting oxidative bursts. In disease, it spreads hematogenously to spleen, liver, bone marrow, and joints, establishing lifelong chronic infections if untreated. Treatment relies on prolonged antibiotic combinations like doxycycline plus rifampin to reduce relapse, though vaccine strains like RB51 pose challenges due to drug resistance; no direct host molecular targets exist, but research explores disrupting bacterial UPR modulation or T4SS for novel therapies. Overall, B. abortus exemplifies a stealth pathogen reliant on host cell hijacking rather than a conventional druggable receptor or enzyme.

Other names
B. abortusBang's disease agent (in cattle context)
02

Mechanism of action

Antibiotics inhibit bacterial protein synthesis (tetracyclines), RNA synthesis (rifampin), or folate synthesis (TMP-SMZ); vaccines like S19 and RB51 induce protective immunity by attenuating bacterial replication

03

Biological functions

Intracellular survival in host cells (e.g., macrophages)evasion of immune responsereplication in pathogen-containing vacuolesmodulation of host vesicular trafficking and ER stress pathways
04

Disease associations

Infection (brucellosis, zoonotic disease causing abortion in animals, chronic fever and complications like endocarditis in humans)
05

Safety considerations

High relapse rates with monotherapy (up to 3-6 months post-treatment)need for prolonged combination therapy (minimum 6 weeks, up to 4-6 months for complications)resistance in vaccine strains (e.g., RB51 to rifampin)case-fatality <1% but chronic persistence possible
06

Interacting drugs

Doxycycline

3 more in the full profile.

Beyond the preview

Go deeper on Brucella abortus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brucella abortus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call